WHO ICTRP trial
Efficacy and safety of bevacizumab plus gefitinib as maintenance therapy in…
ChiCTR-OPN-16008570 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-OPN-16008570 |
|---|---|
| Public title | Efficacy and safety of bevacizumab plus gefitinib as maintenance therapy in patients with non-squamous non-small cell lung cancer patients |
| Scientific title | Efficacy and safety of bevacizumab plus gefitinib as maintenance therapy in patients with non-squamous non-small cell lung cancer patients |
| Primary sponsor | first Affiliated Hospital of Third Military Medicine University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | Post-market |
| Countries | China |
| Conditions | Non-small cell lung cancer |
| Interventions | BevG group:bevacizumab plus gefitinib;G group:gefitib |
| Registration date | May 31, 2016 |
| Target size | BevG group:120;G group:120 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: